Skip to navigation Skip to content

Clinical Trial: Improving cognition in people with progressive MS


Treatment mode of action: To improve cognitive function
Number of Subjects: 40
Medication: cognitive rehabilitation and exercise
Location: Alabama|New Jersey|New York|Pennsylvania
Institutions: Please see below Contact Information
Please see below


MS Society of Canada


Please note: The study sites for this trial are in Birmingham, AL, and East Hanover, NJ. Participation will require travel to those locations.

Participants are people aged 25 to 65, with a diagnosis of progressive MS, who are not dependent on a wheelchair for mobility. Participants will receive compensation for participation.

The study examines the effects of combining cognitive rehabilitation and exercise as a form of intervention in the treatment of cognitive dysfunction in people with progressive MS. Participants are asked to come to the center for a baseline screening followed by intervention visits consisting of exercise and cognitive rehabilitation two times per week for a total of 24 testing sessions over 12 weeks. Upon completion of the intervention, participants return for a short term follow-up assessment, a long term follow-up assessment 6 months after completing the intervention, as well as a virtual follow-up to be completed one year and two years after completing the intervention. At the time of the baseline, short term and long term follow-up screenings, an optional MRI portion of the study is administered. Participants will complete a testing session during a fMRI scan.

Site Contact Information

Petra Silic
Exercise Neuroscience Research Laboratory
Department of Physical Therapy
Community Health Services Bldg 19th, Suite 301
933 19th Street South, Birmingham, AL 35205
Phone: 205-975-1336 

New Jersey
Blake Bichler
Kessler Foundation
Address: 120 Eagle Rock Ave. East Hanover, NJ 07936
Phone: 973-324-0828


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.